Sichuan Kelun Pharmaceutical Co. Ltd. has discovered new lanosterol 14α-demethylase (CYP51) inhibitors reported to be useful for the treatment of Candidal infection and aspergillosis.
Azole antifungal agents are widely used to treat invasive fungal infections (IFIs), which are life-threatening in immunocompromised patients such as those undergoing chemotherapy, transplantation or intensive care.
Convelo Therapeutics Inc. and Genentech Inc. have identified lanosterol 14α-demethylase (CYP51A1; CYP51) inhibitors reported to be useful for the treatment of multiple sclerosis, encephalomyelitis, optic neuritis, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.
